Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Failure
100%
Heart Failure
56%
Empagliflozin
46%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
42%
Angiotensin
40%
Renin
40%
Heart Failure with Reduced Ejection Fraction
32%
Placebo
31%
Hyperkalemia
30%
Isotopes of Potassium
27%
Dipeptidyl Carboxypeptidase Inhibitor
24%
Epidemiology
20%
Aldosterone
20%
Ketone Bodies
20%
Angiotensin Receptor Antagonist
16%
Brain Natriuretic Peptide
13%
All Cause Mortality
9%
Diuretic Agent
8%
Dyspnea
8%
Angiotensin Receptor
8%
Acute Coronary Syndrome
8%
Glucosuria
7%
Cotransporter
5%
Heart Death
5%
Keyphrases
Acute Heart Failure
60%
Heart Failure with Preserved Ejection Fraction (HFpEF)
32%
Angiotensin-converting Enzyme Inhibitor (ACEi)
27%
Heart Failure Hospitalization
26%
Hyperkalemia
24%
BIOSTAT-CHF
20%
Potassium
20%
Renin-angiotensin-aldosterone System Inhibitors
20%
Angiotensin Receptor Blockers
20%
Renin-angiotensin
20%
Renal Glucose Reabsorption
20%
Longitudinal Change
20%
Ketone Bodies
20%
Precipitating Factors
20%
Hospitalization
20%
Potassium Levels
16%
Serum Potassium
16%
Acute Decompensated Heart Failure
12%
Patients with Heart Failure
12%
All-cause Mortality
10%
Acetone
8%
High Potassium
8%
Up-titration
8%
Angiotensin II Type 1 Receptor (AT1R)
8%
Preserved Ejection Fraction
8%
Uncontrolled Hypertension
8%
North America
8%
Acute Coronary Syndrome
8%
Non-adherence
8%
Western Europe
8%
Adherence to Diet
8%
Empagliflozin
6%
